CVR: 30197372
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond is a Danish company of the type Erhvervsdrivende fond based in København Ø, founded in 2006. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Kristine Madsen. The company has 2 employees. In 2025, the company reported a gross profit of DKK 7,463,032 and a net result of DKK -334,181 compared with DKK 1,408,745 the year before. Equity amounted to DKK 4,906,927.
Your company? Claim the profile and show your logo, website and social channels — for free.
Claim this profileFonden er en selvejende institution, der er oprettet med henblik på at yde støtte til følgende formål: Forskning i gynækologisk cancer
| Year | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 7.5 mio. | -334 t. | 28 mio. | 4.9 mio. | 15 | |
| 2024 | 7 mio. | 1.4 mio. | 26.5 mio. | 5.2 mio. | 12 | |
| 2023 | 7.1 mio. | 1.1 mio. | 28.3 mio. | 3.8 mio. | 12 | |
| 2022 | 7.4 mio. | 467 t. | 25.6 mio. | 2.7 mio. | 12 | |
| 2021 | 4.6 mio. | -631 t. | 23.4 mio. | 2.3 mio. | 10 | |
| 2020 | 4.5 mio. | -238 t. | 18.5 mio. | 2.9 mio. | 10 | |
| 2019 | 5.8 mio. | 1.3 mio. | 24.2 mio. | 3.1 mio. | 10 |
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorCompared to 1.044 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond has published its annual report for 2025. Gross profit came to DKK 7,463,032, and the net result was DKK -334,181.
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond has published its annual report for 2024. Gross profit came to DKK 7,031,626, and the net result was DKK 1,408,745.
As of April 14, 2025, Kristine Madsen is registered as director of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of April 14, 2025, Mansoor Raza Mirza has stepped down as director of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 27, 2024, Trine Jakobi Nøttrup has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 27, 2024, Charlotte Aaquist Haslund has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 27, 2024, Line Bjørge has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 27, 2024, Hanna Mikaela Dahlstrand has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 27, 2024, Petra Susanne Malander has left the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 27, 2024, Ane Gerda Zahl Eriksson has left the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 26, 2024, Trine Jakobi Nøttrup has left the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 26, 2024, Line Bjørge has left the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond has published its annual report for 2023. Gross profit came to DKK 7,068,563, and the net result was DKK 1,086,129.
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond has published its annual report for 2022. Gross profit came to DKK 7,416,455, and the net result was DKK 466,886.
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond has published its annual report for 2021. Gross profit came to DKK 4,563,506, and the net result was DKK -631,427.
As of November 1, 2021, Trine Jakobi Nøttrup has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 1, 2021, Line Bjørge has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 1, 2021, Suvi-Annika Kristiina Auranen has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 1, 2021, Ane Gerda Zahl Eriksson has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 1, 2021, Henrik Michael Herluf Roed has left the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 1, 2021, Maarit Anita Anttila has left the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of October 31, 2021, Line Bjørge has left the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of October 31, 2021, Suvi-Annika Kristiina Auranen has left the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond has published its annual report for 2020. Gross profit came to DKK 4,524,460, and the net result was DKK -237,815.
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond has published its annual report for 2019. Gross profit came to DKK 5,751,063, and the net result was DKK 1,316,612.
As of November 28, 2019, Grant Thornton, Godkendt Revisionspartnerselskab has been appointed auditor of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 28, 2019, BDO Holding VII, statsautoriseret revisionsaktieselskab has stepped down as auditor of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 29, 2018, Maarit Anita Anttila has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 29, 2018, Elisabeth Helena Åvall-Lundqvist has left the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of October 18, 2018, Henrik Michael Herluf Roed has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of October 18, 2018, Line Bjørge has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of October 18, 2018, Petra Susanne Malander has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of October 18, 2018, Johanna Unelma Mäenpää has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of October 18, 2018, Suvi-Annika Kristiina Auranen has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of October 18, 2018, Elisabeth Helena Åvall-Lundqvist has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of October 18, 2018, Johanna Unelma Mäenpää has left the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of October 18, 2018, Mansoor Raza Mirza is registered as director of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of April 16, 2018, BDO Holding VII, statsautoriseret revisionsaktieselskab has been appointed auditor of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond was founded on October 1, 2006.
Companies in the same industry and area
CVR 46314964
CVR 45011879
CVR 46496981
CVR 45436497
CVR 46481585
companydata.dk